fashion -WSS

fashion

author：hotspot 2025-10-02 08:49:06 - browse：84194

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The debate over Covid

focus

WSS

A Greenpeace activist is fined for crash

Antibiotic resistance and the global rise in human conflict

Vermont grapples with historic flooding as more rainstorms head for Northeast

Women's World Cup brings attention to abuse in soccer

China sends large group of warplanes, navy ships towards Taiwan in forceful display

France's anti

knowledge

fashion

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

The biotech scorecard for Q1: 17 stock

FDA approval of Sarepta Duchenne genetic therapy gives me hope

GSK Flovent asthma inhalers replaced by authorized generics

How to save PrEP access — and even expand it

Antibody drugs appear effective. Now can we make enough of them?

Medicare details structure of new drug price negotiation program

Inflation cooled significantly in June, bringing price hikes close to normal levels

Virginia high school admissions case could be legal follow

The debate over Covid

explore

Goldman Sachs launches $650M fund for life science investments

After half a century, Israel moves to evict squatter from his cave home on the beach

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Chronically ill young patients struggle to find fertility info

Videos point to link between seizures and unexplained toddler deaths

Federal weight loss drug coverage is 30 years out of date

focus

explore

focus

focus